In this double-blind , phase @ study , @ patients with psoriatic arthritis were randomly assigned in a @:@:@ ratio to receive intravenous secukinumab ( at a dose of @ mg per kilogram ) at weeks @ , @ , and @ , followed by subcutaneous secukinumab at a dose of either @ mg or @ mg every @ weeks , or placebo .